Latest news with #Mangless
Yahoo
6 days ago
- Business
- Yahoo
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) ('Zevra,' or the 'Company'), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Elections following the Company's 2025 Annual Meeting of Stockholders (the 'Annual Meeting'), stockholders have voted to re-elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors (the 'Board') as Class I Directors to serve until the 2028 Annual Meeting. The Zevra Board issued the following statement: 'We thank all our stockholders for their strong participation in the voting process and continued support of Zevra. The overwhelming support for the Company's nominees represents a clear endorsement of our strategic direction from our stockholder base. Over the past two years, we have taken decisive action to transform Zevra into a stronger, growth-oriented commercial organization focused on making a positive impact for patients living with rare diseases. This vote validates our progress to date and reinforces our confidence in our strategic plan as we continue building momentum and drive long-term value for our stockholders.' As previously disclosed, Daniel J. Mangless, a stockholder of the Company, indicated his intention to nominate Travis C. Mickle, Ph.D. and Arthur C. Regan for election as directors at the Annual Meeting, in opposition to Dr. Dixon and Ms. Favorito. However, Mr. Mangless subsequently failed to comply with the applicable requirements of the Securities and Exchange Commission's (the 'SEC's') proxy rules and the Company's amended and restated bylaws (the 'Bylaws') to proceed with a valid nomination. Specifically, Mr. Mangless failed to solicit at least 67% of the voting power of the shares entitled to vote on the election of directors at the Annual Meeting, as required by SEC rules and the Bylaws, and failed to provide the Company with reasonable evidence of such solicitation, as required by the Bylaws. Finally, Mr. Mangless did not attend the Annual Meeting to validly nominate his nominees, as required by the Bylaws. As a result of Mr. Mangless' failure to meet these requirements and as provided by the Bylaws, Mr. Mangless' nominations were disregarded. Based on results from the independent Inspector of Elections for the Annual Meeting, if Mr. Mangless had complied with the applicable requirements to validly nominate his nominees, Dr. Mickle would have received just 26.45% of the vote and Mr. Regan would have received just 23.97% of the vote, compared to 73.97% and 73.41% for Dr. Dixon and Ms. Favorito, respectively. The outcome of the election underscores stockholders' strong support for Zevra's Board – including its deep industry expertise, proven track record, and steadfast commitment to delivering value. Looking ahead, and now with a clear mandate from stockholders, the Board and management team are focused on accelerating Zevra's disciplined strategy and value-creation initiatives. Additionally, stockholders approved the proposal to ratify the appointment of Ernst & Young LLP as the Company's independent auditors for the fiscal year ending December 31, 2025. The final certified results, as confirmed by the independent Inspector of Elections, will be filed on a Form 8-K with the SEC. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. Expanded access programs are made available by Zevra Therapeutics, Inc. and its affiliates and are subject to the Company's Expanded Access Program ('EAP') policy, as published on its website. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion. For more information, please visit or follow us on X and LinkedIn. Cautionary Note Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's actions to enhance stockholder value, the Company's plans with respect to director candidates nominated by stockholders; our strategic, financial, operational, corporate governance, executive compensation, and product development objectives; and the timing of any of the foregoing. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, and Zevra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 13, 2025, and Zevra's other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Contacts For investor inquiries Nichol Ochsner+1 (732) 754-2545nochsner@ For media inquiries FTI Consulting Tanner Kaufman / Kyla MacLennan / Mike Gaudreauzevratherapeutics@
Yahoo
21-05-2025
- Business
- Yahoo
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote 'FOR' Wendy L. Dixon, Ph.D. and Tamara A. Favorito on the WHITE Proxy Card and 'WITHHOLD' for Mangless Nominees CELEBRATION, Fla., May 21, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) ('Zevra,' or the 'Company'), a commercial-stage company focused on providing therapies to people living with rare disease, today announced that all three leading proxy advisory firms, Institutional Shareholder Services ('ISS'), Glass Lewis & Co. ('Glass Lewis'), and Egan-Jones Proxy Services ('Egan-Jones') have recommended that stockholders vote 'FOR' Wendy L. Dixon, Ph.D. and Tamara A. Favorito and 'WITHHOLD' on dissident nominees Travis Mickle and Arthur Regan on the WHITE proxy card at the upcoming 2025 Annual Meeting of Stockholders, scheduled to be held on May 29, 2025 (the 'Annual Meeting'). In response to the positive recommendations from all three leading proxy advisors, the Zevra Board of Directors issued the following statement: 'We are pleased that all three leading proxy advisory firms – ISS, Glass Lewis, and Egan-Jones – unanimously endorsed Zevra's current Board and strategic direction. These independent third-party recommendations validate our position that Mangless has failed to present a compelling case for change. Our Board and management team remain committed to serving our stockholders and continuing the significant value creation we've delivered under current leadership.' All three proxy advisors concluded that Mangless (the 'dissident') has provided insufficient arguments to justify electing its nominees to the Board, and has failed to present a case for change.1 ISS said, '…based on the limited information available in the public domain, the dissident has presented a case for change that would be insufficient for a minority position, let alone the majority position that is effectively being sought…' Glass Lewis acknowledged that Mangless failed to provide any clear strategy or explanation of what he intends to accomplish or how he proposes to increase stockholder value, noting, 'While we consider the sum of available arguments already weighs meaningfully against the Dissident agenda, we believe it is worth stressing that Mr. Mangless has forwarded no meaningful alternate tack for Zevra. More pointedly, we identify no clear plan of action to improve Zevra's operational efficacy and no concrete path to further increase shareholder value…' Egan-Jones stated that, '…given the positive momentum Zevra Therapeutics is experiencing in its strategic execution, electing the dissident nominees would be disruptive and could impede value creation.' All three proxy advisors emphasized the significant and outsized total shareholder returns under Zevra's current management team. Notably, ISS stated, 'The company has meaningfully outperformed the broader biotech market over all periods of measurement, including McFarlane's tenure as CEO. TSR outperformance was largely stimulated by the initial news reports of positive outcomes from Miplyffa, but the company has continued to outperform since then.' Egan-Jones further highlighted that, '…the past two years have yielded exceptional returns that have outpaced both the total market (as represented by the VTI) and the S&P Biotech ETF (XBI).' All three proxy advisors agree that Mangless' nominees are not the right nominees for Zevra's Board. ISS, in fact, stated, '…it is unclear how the dissident nominees, which include the former CEO, would be able to contribute without disrupting the company's positive momentum. In other words, the facts and circumstances in this specific case suggest that there is a compelling reason to support both management nominees.' ISS added, '...the board's concerns about having a former CEO on the board and potential disruption are valid.' Glass Lewis highlighted, 'Mr. Regan has limited, dated, and unrelated public board service,' and that 'publication of certain social media activity by Mr. Regan appears to suggest something of a blithe approach to compliance...' Egan-Jones questioned the relevant expertise of Mangless' nominees, stating, '…we do not believe Mr. Regan's background in proxy solicitation offers meaningful value in the context of Zevra's boardroom.' YOUR VOTE MATTERS:VOTE THE WHITE PROXY CARD TODAY Zevra's Board of Directors urges stockholders to only use the WHITE proxy card to vote "FOR" the re-election of Wendy Dixon, Ph.D. and Tamara A. Favorito to the Company's Board as Class I directors to hold office until the 2028 Annual Meeting of Stockholders. If you receive a BLUE proxy card from Mr. Mangless, please disregard. The Board strongly recommends that stockholders protect their investment in Zevra by casting their vote as soon as possible, regardless of plans to attend the Annual Meeting on May 29, 2025. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. Expanded access programs are made available by Zevra Therapeutics, Inc. and its affiliates and are subject to the Company's Expanded Access Program (EAP) policy, as published on its website. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion. For more information, please visit or follow us on X and LinkedIn. Cautionary Note Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's actions to enhance stockholder value, the Company's plans with respect to director candidates nominated by stockholders; sale of the PRV and anticipated proceeds therefrom; our strategic, financial, operational, corporate governance, executive compensation, and product development objectives; and the timing of any of the foregoing. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025 and Zevra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 13, 2025, and Zevra's other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Additional Information and Where to Find It Zevra has filed with the SEC a definitive proxy statement on Schedule 14A, containing a form of WHITE proxy card, with respect to its solicitation of proxies for the 2025 Annual Meeting of Stockholders. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY ZEVRA, AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED BY ZEVRA WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION. Investors and security holders may obtain copies of these documents and other documents filed with the SEC by Zevra free of charge through the website maintained by the SEC at Copies of the documents filed by Zevra are also available free of charge by accessing Zevra's investor relations website at Participants in the Solicitation Zevra, its directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies with respect to a solicitation by Zevra. Information about Zevra's executive officers and directors is available under the heading 'Information about our Executive Officers and Directors' in Part I of Zevra's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 12, 2025 and under the headings 'Proposal 1: Election of Directors,' 'Executive Officers,' 'Security Ownership of Certain Beneficial Owners and Management' and 'Executive Compensation,' and 'Director Compensation' in Zevra's definitive proxy statement on Schedule 14A for its annual meeting of stockholders to be held in 2025, which was filed with the SEC on April 21, 2025. To the extent holdings of our directors and executive officers of Zevra securities reported in such definitive proxy statement change, such changes will be reflected on Statements of Change in Ownership on Forms 3, 4 or 5 filed with the SEC. These documents are available free of charge at the SEC's website at Copies of the documents are also available free of charge by accessing Zevra's investor relations website at Contacts For investor inquiries Nichol Ochsner+1 (732) 754-2545nochsner@ For media inquiries FTI ConsultingTanner Kaufman / Kyla MacLennan / Mike Gaudreauzevratherapeutics@ _______________ 1 Permission to use quotes from the ISS report, the Glass Lewis report, and the Egan-Jones report was neither sought nor in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
